Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.17 -0.33 (-0.21%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,265,969
Open 155.90
Bid (Size) 155.00 (6)
Ask (Size) 155.49 (10)
Prev. Close 155.50
Today's Range 154.11 - 157.12
52wk Range 143.13 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 3.20%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Dividend Stocks That Are Screaming Buys in November
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends. 
Via The Motley Fool
2 Unstoppable Dividend Stocks to Buy Now With $500
Via The Motley Fool

Performance

YTD
-3.00%
-3.00%
1 Month
-6.45%
-6.45%
3 Month
-5.46%
-5.46%
6 Month
+5.58%
+5.58%
1 Year
+1.75%
+1.75%

More News

Read More
2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
Spotlight on Johnson & Johnson: Analyzing the Surge in Options Activity
Via Benzinga
Price Over Earnings Overview: Johnson & Johnson
Via Benzinga
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Via MarketBeat
This Is What Whales Are Betting On Johnson & Johnson
Via Benzinga
Industry Comparison: Evaluating Johnson & Johnson Against Competitors In Pharmaceuticals Industry
Via Benzinga
Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
This Johnson & Johnson Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower
Via Benzinga
Topics Government
Exposures Political
Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology
Via Talk Markets
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Johnson & Johnson Challenges Government Drug Pricing Dispute Over Two Drugs
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
Via The Motley Fool
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
From Inovalon Holdings, Inc.
Via GlobeNewswire
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
Via Benzinga
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
Via Benzinga
3 Dividend Growth Stocks You Can Buy and Hold Forever
Via The Motley Fool
Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
Via Benzinga
Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government
Via The Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
Via The Motley Fool
Topics ETFs
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.